Table 4.
Comparison of patients with Vancouver type B1 PFF (Means ± SD)
| Group I (TXA) | Group II (No‐TXA) | P‐value | |
|---|---|---|---|
| Cases (n) | 17 | 16 | ‐ |
| Age (years) | 72.8 ± 14.1 | 68.9 ± 14.2 | 0.444* |
| Gender (male/female) | 6/11 | 8/8 | 0.491† |
| BMI (kg/m2) | 23.1 ± 3.3 | 24.4 ± 2.2 | 0.195* |
| Surgical time (min) | 64.4 ± 16.9 | 65.6 ± 46.9 | 0.838* |
| Estimated intraoperative blood loss (mL) | 320.0 ± 177.3 | 931.3 ± 549.8 | ˂0.001‡ |
| Visible blood loss (mL) | 572.9 ± 311.9 | 1622.5 ± 894.9 | ˂0.001‡ |
| Hidden blood loss (mL) | 646.1 ± 625.7 | 1482.2 ± 1157.6 | 0.008‡ |
| Allogeneic blood transfusion rate | 47.1% | 75.0% | 0.157† |
| Allogeneic blood transfusion volume (mL) | 302.9 ± 394.7 | 1403.1 ± 1384.0 | 0.011‡ |
| Symptomatic VTE (cases/incidence) | 0 (0%) | 1 (6.3%) | 0.485† |
*
Student's t test.
†
Fisher's exact probabilities test.
‡
Mann–Whitney U test.
BMI, body mass index; PFF, periprosthetic femur fractures; TXA, tranexamic acid; VTE, venous thromboembolism.